Summit Therapeutics Inc. (NASDAQ:SMMT – Get Rating) CEO Mahkam Zanganeh bought 15,973,743 shares of the business’s stock in a transaction dated Wednesday, March 8th. The shares were purchased at an average price of $1.05 per share, for a total transaction of $16,772,430.15. Following the transaction, the chief executive officer now directly owns 23,395,269 shares of the company’s stock, valued at approximately $24,565,032.45. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Summit Therapeutics Stock Performance
Shares of Summit Therapeutics stock opened at $1.42 on Friday. The company’s fifty day moving average is $3.16 and its two-hundred day moving average is $2.16. Summit Therapeutics Inc. has a 1 year low of $0.66 and a 1 year high of $5.78. The company has a market capitalization of $285.87 million, a P/E ratio of -1.75 and a beta of -1.01.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 1st.
Hedge Funds Weigh In On Summit Therapeutics
Summit Therapeutics Company Profile
Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
- Get a free copy of the StockNews.com research report on Summit Therapeutics (SMMT)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.